Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-22-PCRP-IDA: DoD Prostate Cancer, Idea Development Award

Closed Closed July 28, 2022 Opportunity W81XWH-22-PCRP-IDA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2022.

• Total funding$44.6 million
• Expected awards31
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY22 PCRP Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP Mission. The key components of this award mechanism are: • Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Projects involving multidisciplinary and/or data science approaches are especially encouraged. • Impact: Applications are required to address and provide a solution to one or more of the FY22 PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the FY22 PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. • Preliminary Data: Due to this award’s emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data are included, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature. To maximize the potential for impact, investigators are strongly encouraged to incorporate the following components into their study design where appropriate: authentication of proposed cell lines; statistical rigor of preclinical animal experiments and epidemiological studies; incorporation of experiments to assess clinical relevance and translatability of findings; and validation in patient cohorts. Investigators considering use of resources are highly encouraged to provide a letter of support indicating access to and the availability of the desired resources to support the study. New Investigator category: The FY22 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.